(KDP) Keurig Dr Pepper - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US49271V1008
Stock: Coffee, Soft Drinks, Water, Tea
Total Rating 34
Risk 57
Buy Signal -0.24
| Risk 5d forecast | |
|---|---|
| Volatility | 24.8% |
| Relative Tail Risk | -3.99% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.54 |
| Alpha | -16.89 |
| Character TTM | |
|---|---|
| Beta | 0.023 |
| Beta Downside | 0.235 |
| Drawdowns 3y | |
|---|---|
| Max DD | 30.99% |
| CAGR/Max DD | -0.12 |
EPS (Earnings per Share)
Revenue
Description: KDP Keurig Dr Pepper March 05, 2026
Keurig Dr Pepper Inc. manufactures and distributes beverages and single-serve brewing systems. The company operates in the U.S. and internationally.
KDPs business model includes three segments: U.S. Refreshment Beverages, U.S. Coffee, and International. They produce and sell branded concentrates, syrups, finished beverages, and single-serve coffee products like K-Cup pods and brewers. The beverage industry is characterized by strong brand loyalty and extensive distribution networks.
KDPs portfolio includes numerous owned and licensed brands such as Dr Pepper, Snapple, Green Mountain Coffee Roasters, and McCafé. These products are sold through various channels, including supermarkets, mass merchandisers, convenience stores, and e-commerce platforms. Distribution to diverse retail outlets is critical for consumer packaged goods companies.
For more detailed financial analysis, ValueRay provides comprehensive data on companies like KDP.
Headlines to watch out for
- Coffee pod sales drive U.S. Coffee segment revenue
- Beverage concentrate sales impact U.S. Refreshment revenue
- International segment growth expands global market share
- Commodity price fluctuations affect production costs
- Consumer spending on beverages influences sales volume
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 2.08b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.28 > 1.0 |
| NWC/Revenue: -18.21% < 20% (prev -26.64%; Δ 8.43% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.99b > Net Income 2.08b |
| Net Debt (15.12b) to EBITDA (4.03b): 3.75 < 3 |
| Current Ratio: 0.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.36b) vs 12m ago -0.40% < -2% |
| Gross Margin: 54.20% > 18% (prev 0.56%; Δ 5365 % > 0.5%) |
| Asset Turnover: 30.50% > 50% (prev 28.73%; Δ 1.76% > 0%) |
| Interest Coverage Ratio: 4.73 > 6 (EBITDA TTM 4.03b / Interest Expense TTM 727.0m) |
Altman Z'' 0.60
| A: -0.05 (Total Current Assets 5.27b - Total Current Liabilities 8.29b) / Total Assets 55.46b |
| B: 0.10 (Retained Earnings 5.62b / Total Assets 55.46b) |
| C: 0.06 (EBIT TTM 3.44b / Avg Total Assets 54.44b) |
| D: 0.19 (Book Value of Equity 5.74b / Total Liabilities 29.94b) |
| Altman-Z'' Score: 0.60 = B |
Beneish M -3.03
| DSRI: 0.90 (Receivables 1.67b/1.72b, Revenue 16.60b/15.35b) |
| GMI: 1.03 (GM 54.20% / 55.56%) |
| AQI: 0.99 (AQ_t 0.85 / AQ_t-1 0.85) |
| SGI: 1.08 (Revenue 16.60b / 15.35b) |
| TATA: 0.00 (NI 2.08b - CFO 1.99b) / TA 55.46b) |
| Beneish M-Score: -3.03 (Cap -4..+1) = AA |
What is the price of KDP shares?
As of March 09, 2026, the stock is trading at USD 28.25 with a total of 7,450,099 shares traded.
Over the past week, the price has changed by -5.74%, over one month by -0.91%, over three months by -1.78% and over the past year by -10.46%.
Over the past week, the price has changed by -5.74%, over one month by -0.91%, over three months by -1.78% and over the past year by -10.46%.
Is KDP a buy, sell or hold?
Keurig Dr Pepper has received a consensus analysts rating of 4.10.
Therefore, it is recommended to buy KDP.
- StrongBuy: 9
- Buy: 5
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the KDP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 35.6 | 25.9% |
| Analysts Target Price | 35.6 | 25.9% |
KDP Fundamental Data Overview March 09, 2026
P/E Trailing = 18.4641
P/E Forward = 12.7877
P/S = 2.3118
P/B = 1.4936
P/EG = 0.6878
Revenue TTM = 16.60b USD
EBIT TTM = 3.44b USD
EBITDA TTM = 4.03b USD
Long Term Debt = 13.04b USD (from longTermDebt, last quarter)
Short Term Debt = 3.10b USD (from shortTermDebt, last quarter)
Debt = 16.14b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 15.12b USD (from netDebt column, last quarter)
Enterprise Value = 53.50b USD (38.38b + Debt 16.14b - CCE 1.03b)
Interest Coverage Ratio = 4.73 (Ebit TTM 3.44b / Interest Expense TTM 727.0m)
EV/FCF = 35.55x (Enterprise Value 53.50b / FCF TTM 1.50b)
FCF Yield = 2.81% (FCF TTM 1.50b / Enterprise Value 53.50b)
FCF Margin = 9.06% (FCF TTM 1.50b / Revenue TTM 16.60b)
Net Margin = 12.52% (Net Income TTM 2.08b / Revenue TTM 16.60b)
Gross Margin = 54.20% ((Revenue TTM 16.60b - Cost of Revenue TTM 7.60b) / Revenue TTM)
Gross Margin QoQ = 53.77% (prev 54.34%)
Tobins Q-Ratio = 0.96 (Enterprise Value 53.50b / Total Assets 55.46b)
Interest Expense / Debt = 1.47% (Interest Expense 238.0m / Debt 16.14b)
Taxrate = 22.76% (104.0m / 457.0m)
NOPAT = 2.66b (EBIT 3.44b * (1 - 22.76%))
Current Ratio = 0.64 (Total Current Assets 5.27b / Total Current Liabilities 8.29b)
Debt / Equity = 0.63 (Debt 16.14b / totalStockholderEquity, last quarter 25.52b)
Debt / EBITDA = 3.75 (Net Debt 15.12b / EBITDA 4.03b)
Debt / FCF = 10.04 (Net Debt 15.12b / FCF TTM 1.50b)
Total Stockholder Equity = 25.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.82% (Net Income 2.08b / Total Assets 55.46b)
RoE = 8.29% (Net Income TTM 2.08b / Total Stockholder Equity 25.07b)
RoCE = 9.03% (EBIT 3.44b / Capital Employed (Equity 25.07b + L.T.Debt 13.04b))
RoIC = 6.48% (NOPAT 2.66b / Invested Capital 41.01b)
WACC = 4.56% (E(38.38b)/V(54.52b) * Re(6.0%) + D(16.14b)/V(54.52b) * Rd(1.47%) * (1-Tc(0.23)))
Discount Rate = 6.0% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.38%
[DCF] Terminal Value 83.86% ; FCFF base≈1.54b ; Y1≈1.24b ; Y5≈852.5m
[DCF] Fair Price = 8.14 (EV 26.18b - Net Debt 15.12b = Equity 11.07b / Shares 1.36b; r=5.90% [WACC]; 5y FCF grow -23.32% → 2.90% )
EPS Correlation: 63.96 | EPS CAGR: 17.28% | SUE: 0.47 | # QB: 0
Revenue Correlation: 79.18 | Revenue CAGR: 10.65% | SUE: 2.98 | # QB: 2
EPS next Quarter (2026-06-30): EPS=0.57 | Chg7d=+0.042 | Chg30d=+0.038 | Revisions Net=+9 | Analysts=10
EPS current Year (2026-12-31): EPS=2.23 | Chg7d=+0.066 | Chg30d=+0.062 | Revisions Net=+10 | Growth EPS=+8.9% | Growth Revenue=+54.6%
EPS next Year (2027-12-31): EPS=2.51 | Chg7d=+0.196 | Chg30d=+0.200 | Revisions Net=+6 | Growth EPS=+12.3% | Growth Revenue=+16.4%
[Analyst] Revisions Ratio: +1.00 (9 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.5% (Discount Rate 7.9% - Earnings Yield 5.4%)
[Growth] Growth Spread = +71.1% (Analyst 73.7% - Implied 2.5%)
P/E Forward = 12.7877
P/S = 2.3118
P/B = 1.4936
P/EG = 0.6878
Revenue TTM = 16.60b USD
EBIT TTM = 3.44b USD
EBITDA TTM = 4.03b USD
Long Term Debt = 13.04b USD (from longTermDebt, last quarter)
Short Term Debt = 3.10b USD (from shortTermDebt, last quarter)
Debt = 16.14b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 15.12b USD (from netDebt column, last quarter)
Enterprise Value = 53.50b USD (38.38b + Debt 16.14b - CCE 1.03b)
Interest Coverage Ratio = 4.73 (Ebit TTM 3.44b / Interest Expense TTM 727.0m)
EV/FCF = 35.55x (Enterprise Value 53.50b / FCF TTM 1.50b)
FCF Yield = 2.81% (FCF TTM 1.50b / Enterprise Value 53.50b)
FCF Margin = 9.06% (FCF TTM 1.50b / Revenue TTM 16.60b)
Net Margin = 12.52% (Net Income TTM 2.08b / Revenue TTM 16.60b)
Gross Margin = 54.20% ((Revenue TTM 16.60b - Cost of Revenue TTM 7.60b) / Revenue TTM)
Gross Margin QoQ = 53.77% (prev 54.34%)
Tobins Q-Ratio = 0.96 (Enterprise Value 53.50b / Total Assets 55.46b)
Interest Expense / Debt = 1.47% (Interest Expense 238.0m / Debt 16.14b)
Taxrate = 22.76% (104.0m / 457.0m)
NOPAT = 2.66b (EBIT 3.44b * (1 - 22.76%))
Current Ratio = 0.64 (Total Current Assets 5.27b / Total Current Liabilities 8.29b)
Debt / Equity = 0.63 (Debt 16.14b / totalStockholderEquity, last quarter 25.52b)
Debt / EBITDA = 3.75 (Net Debt 15.12b / EBITDA 4.03b)
Debt / FCF = 10.04 (Net Debt 15.12b / FCF TTM 1.50b)
Total Stockholder Equity = 25.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.82% (Net Income 2.08b / Total Assets 55.46b)
RoE = 8.29% (Net Income TTM 2.08b / Total Stockholder Equity 25.07b)
RoCE = 9.03% (EBIT 3.44b / Capital Employed (Equity 25.07b + L.T.Debt 13.04b))
RoIC = 6.48% (NOPAT 2.66b / Invested Capital 41.01b)
WACC = 4.56% (E(38.38b)/V(54.52b) * Re(6.0%) + D(16.14b)/V(54.52b) * Rd(1.47%) * (1-Tc(0.23)))
Discount Rate = 6.0% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.38%
[DCF] Terminal Value 83.86% ; FCFF base≈1.54b ; Y1≈1.24b ; Y5≈852.5m
[DCF] Fair Price = 8.14 (EV 26.18b - Net Debt 15.12b = Equity 11.07b / Shares 1.36b; r=5.90% [WACC]; 5y FCF grow -23.32% → 2.90% )
EPS Correlation: 63.96 | EPS CAGR: 17.28% | SUE: 0.47 | # QB: 0
Revenue Correlation: 79.18 | Revenue CAGR: 10.65% | SUE: 2.98 | # QB: 2
EPS next Quarter (2026-06-30): EPS=0.57 | Chg7d=+0.042 | Chg30d=+0.038 | Revisions Net=+9 | Analysts=10
EPS current Year (2026-12-31): EPS=2.23 | Chg7d=+0.066 | Chg30d=+0.062 | Revisions Net=+10 | Growth EPS=+8.9% | Growth Revenue=+54.6%
EPS next Year (2027-12-31): EPS=2.51 | Chg7d=+0.196 | Chg30d=+0.200 | Revisions Net=+6 | Growth EPS=+12.3% | Growth Revenue=+16.4%
[Analyst] Revisions Ratio: +1.00 (9 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.5% (Discount Rate 7.9% - Earnings Yield 5.4%)
[Growth] Growth Spread = +71.1% (Analyst 73.7% - Implied 2.5%)